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Introduction: Extramedullary myeloma that occurs during the clinical course of multiple myeloma is rare but is an
independent poor prognostic factor with mortality of 73% and median survival of 12 months despite aggressive
therapies including novel agents. The clinicopathological aspects, biology and management of extramedullary
myelomas are poorly understood. Our case highlights the pathobiological aspects of this important but rare entity,
and the repercussions of modern therapies.
Case presentation: A 60-year-old Caucasian man initially presented with an anterior rib fracture. Subsequent
workup revealed stage IIIB immunoglobulin G lambda multiple myeloma. A bone marrow biopsy showed sheets of
plasma cells, harboring unfavorable cytogenetics including deletion of 17p and t(4;14). He achieved near complete
remission and resolution of karyotypic abnormalities with three cycles of induction doxorubicin, thalidomide, and
dexamethasone (clinical trial). This was followed by high-dose melphalan and autologous stem cell transplant. He
relapsed 1 year later. His bone marrow at that time showed only a few scattered polyclonal plasma cells. He
received three cycles of bortezomib and tanespimycin (clinical trial) and achieved very good partial response. He
again relapsed 1 year later with multiple large peripheral soft tissue masses and lymph nodes. Biopsies of the
peripheral lesions were consistent with extramedullary myeloma, but repeat bone marrow biopsy continued to
show no evidence of intramedullary disease.
Conclusions: This is one of the few cases reported that illustrates the differential response of extramedullary
compared to intramedullary myeloma to multiple standard combination therapies including novel therapeutics and
transplant, resulting in a very short survival. Several mechanisms for intra-to-extra medullary migration and hence
the differential treatment response have been hypothesized. Physicians should be aware of this problem during
treatment with immunomodulatory drugs and proteasome inhibitors not only in relapsed but also in front-line
setting. In such cases, there is a potential role for evolving targeted therapeutics as we continue to better
understand the tumor biology.
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Multiple myeloma (MM) is a plasma cell malignancy that
remains incurable despite the use of high-dose chemother-
apy with autologous stem cell transplantation (ASCT) [1].
It is the second most common hematological malignancy
following lymphoma, affecting over 20,000 patients each
year in the USA, with nearly 11,000 deaths during the
same time period [2]. MM is a disease characterized by
neoplastic proliferation of monoclonal plasma cells that
lead to lytic bone lesions, hypercalcemia, and renal impair-
ment. Survival of MM may be prolonged with novel
agents such as thalidomide, which has been demonstrated
to be effective for refractory MM [3]. In addition, the com-
bination of melphalan and prednisolone with thalidomide
(MPT) is also an effective first-line treatment for elderly
patients with MM [4].
Plasmacytomas rarely arise outside the bone marrow
because of the favorable microenvironment in the mar-
row. Extramedullary plasmacytoma (EMP) is a plasma
cell neoplasm of soft tissue without bone marrow in-
volvement and hence no systemic signs and symptoms
associated with MM [5]. Therefore they may be inciden-
tally diagnosed on imaging studies obtained for a differ-
ent indication. They are typically solitary, radiosensitive
neoplasms that frequently pursue an indolent clinical
course, constituting approximately 3% of all plasma cell
tumors with a male to female ratio of 3:1 [6], with a low
recurrence rate (<10%) and high 10-year disease-free sur-
vival. The disease may involve a wide variety of anatomic
sites: upper aerodigestive tract comprising nasal/paranasal,
pharynx, trachea and esophagus (85%), pancreas, spleen,
urinary bladder, thyroid, breast and testicles [7]. MM pre-
ceded by an EMP is seen in approximately 15 to 20% of
patients with MM as a manifestation of EMP progression
[7,8]. In contrast, extramedullary MM (eMM) that occurs
during the clinical course of MM is rare, although its inci-
dence is increasing in recent years (Table 1) [1,8], approxi-
mately 14% per the Spanish Registry of Transplants [9].
eMM is an independent poor prognostic factor, with mor-
tality of 73% and median survival of 12 months despite ag-
gressive therapies [10]. Response to immunomodulatory
drugs (IMiDs) in patients with eMM is poor [1,11]. Here
we present an extremely uncommon case of progressive
multiple eMM despite concomitant medullary response
after multiple combination therapies and ASCT. The case
reported here highlights the pathobiological aspects of this
important but rare entity, and the repercussions of mod-
ern therapies.
Case presentation
A 60-year-old Caucasian man initially presented with an
anterior rib fracture which was evaluated with X-rays
that revealed lytic lesions. Subsequent workup for MM
revealed elevated immunoglobulin (Ig) G levels andmasses in his anterior rib that appeared to be plasmacy-
tomas. The results of initial laboratory tests revealed an
IgG lambda paraprotein, serum protein electrophoresis
6.36g/dL, urine protein electrophoresis 1956mg/24
hours, IgG of 8000, lambda free light chain of 151, beta-
2 microglobulin of 10.8, hemoglobin 9.3g/dL and serum
calcium of 14.4mg/dL. A skeletal survey showed involve-
ment of disease with multiple lytic lesions in his skull,
thoracic spine, ribs, clavicle, pelvis, and bilateral upper
and lower extremities. The diagnosis was confirmed by a
bone marrow biopsy, which showed sheets of plasma
cells. Cytogenetics showed hyperdiploidy, trisomy 5 and
9, deletion of 17p, IgH translocation t(4;14), but were
negative for deletion 13q. He was staged as IIIB accord-
ing to the Durie-Salmon staging system. He was started
on induction treatment with a clinical trial using doxo-
rubicin, thalidomide, and dexamethasone. He received
three cycles with resultant near complete remission and
resolution of karyotypic abnormalities. Five months after
induction, he underwent treatment with high-dose mel-
phalan, followed by ASCT. He did well initially after
transplant but relapsed approximately 1 year later. Bone
marrow at that time showed only few scattered poly-
clonal plasma cells. He was started on treatment with
bortezomib and tanespimycin as part of the University
of Kansas Medical Center Institutional Review Board
(IRB)-approved clinical trial after having obtained the
patient’s consent. He achieved a very good partial re-
sponse after three cycles. Following the third cycle he
was taken off the study for failure to tolerate tanespimy-
cin. He did well for approximately 1 year, but relapsed
again with multiple large peripheral lesions including his
left supraclavicular lymph nodes (Figure 1), left antecu-
bital fossa (Figure 2), and left inguinal area. Positron
emission testing revealed numerous soft tissue masses as
shown in Figures 3 and 4. Biopsies of the peripheral lesions
were consistent with eMM, but a repeat bone marrow bi-
opsy continued to show no evidence of intramedullary dis-
ease. He received radiation to above peripheral eMM with
improvement in size and symptoms. Following this he de-
clined further treatment and was placed on palliative care
and expired soon after. To the best of our knowledge, this
is one of the few cases reported of a patient with rapid
extramedullary relapse and progression of disease despite
concomitant medullary response to multiple standard com-
bination therapies including novel therapeutics and ASCT.Discussion
This rare case of myeloma had several unusual features
including unfavorable cytogenetics, progressive eMM
despite concomitant bone marrow response to therapy
and very rapid progression of disease within 12 months
of eMM relapse.
Table 1 List of cases with extramedullary multiple myeloma progression despite concomitant medullary response to multiple myeloma therapy
Case study/series Number of cases Multiple myeloma treatment Bone marrow at extramedullary
multiple myeloma relapse
Extramedullary multiple myeloma relapse course/response
Bairey et al. [12] 1 Chemotherapy No evidence of disease eMM relapse in skin and subcutaneous areas, right
eyebrow, right knee, sternum and right axilla.
Failed chemotherapy. Died secondary to liver eMM.
Iwasaki et al. [13] 1 Chemotherapy No evidence of disease Skin eMM relapse in 6 months which responded to chemotherapy.
Retroperitoneal eMM relapse 2 years later causing death.
Avigdor et al. [11] 2 Chemotherapy followed by ASCT. Relapse
of MM was treated with thalidomide.
No evidence of disease Patient 1 developed parasellar eMM after 3 months of thalidomide and
died in 2 weeks. Patient 2 developed diffuse skin eMM which failed
to respond to Allo SCT.
Ah-Weng et al. [14] 1 Chemotherapy followed by ASCT No evidence of disease Multiple cutaneous eMM in 3 months. VAD salvage chemotherapy
followed by localized RT and IFN-2a attempted but patient died in 2 weeks.
Terpos et al. [10] 15 ASCT or Allo SCT No evidence of disease median time from ASCT to eMM was 24 months. eMM sites included skin,
rectum, and testicles. Treated with local RT (n=5), combination of RT and
chemotherapy or thalidomide (n=7), and chemotherapy +/− thalidomide
(n=2), VAD-chemotherapy and local RT followed by a mini-allograft from
the original donor (n=1). 11 patients died at a median of 10 months
following diagnosis of eMM. 4 patients were still alive at 12–20
months after eMM relapse.
Candoni et al. [15] 3 Thalidomide No evidence of disease Median time to eMM relapse was 3 months. eMM sites included
cutaneous, soft tissue, parasellar. Salvage therapy attempted
but poor clinical outcome.
Cerny et al. [16] 6 IMiD and/or ASCT n/a Median time to progression and survival after eMM relapse
was 29 months and 38 days respectively.
Waterhouse et al. [17] 1 Thalidomide/melphalan followed by ASCT.
MM relapse treated with bortezomib.
No evidence of disease eMM relapse in the brain, pleural and paravertebral soft
tissue in 1 month following bortezomib.
Gozzetti et al. [18] 1 Chemotherapy followed by ASCT No evidence of disease eMM relapse in lung, mediastinum, pancreas, psoas muscle at
5 months post-ASCT. Failed hyper C-PAD. Disease stabilized
on lenalidomide at 10 months from eMM relapse.
Abbreviations: Allo SCT, allogeneic hematopoietic stem cell transplantation; ASCT, autologous stem cell transplantation; eMM, extramedullary multiple myeloma; IFN, interferon; IMiD, immunomodulatory drug; MM,




















Figure 1 Photograph of patient’s left supraclavicular group of
lymph nodes.
Figure 3 Positron emission tomography scan showing
metabolic activity in the enlarged left supraclavicular, inguinal
and abdominal lymph node regions.
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guidelines are unclear for optimal management of this
entity but localized palliative radiotherapy is favored for
symptomatic lesions [19]. Our patient underwent radio-
therapy with improvement in size and symptoms. How-
ever, in recent times, radiotherapy has been outmoded
by bortezomib, a proteasome inhibitor of NF-KB, as the
treatment of choice for eMM due to encouraging out-
comes (<10% local recurrence rate) [1,19,20]. Our pa-
tient did relapse with multiple EMPs within 12 months
of receiving bortezomib. Such increased frequency of
eMM relapse has been reported in the past (Table 1),
hence suggesting a possible causative relation to current
MM therapies.
Thalidomide and lenalidomide (IMiDs) have been rela-
tively recently introduced in the frontline therapy of
MM; the induction for transplant eligible patients has
changed from cytotoxic chemotherapy to a combination
of IMiDs with steroids [21]. Although thalidomide alone
[1] or in combination [8,15] has shown antimyeloma ac-
tivity with both a fall in monoclonal paraprotein levels
and clearance of marrow plasmacytosis, its activity in
eMM appears variable. Overall, patients with eMM do
not appear to attain a good response to IMiDs [1,11,15].
As witnessed in our patient, Candoni et al. in 2008 re-
ported three patients with MM but without extramedul-
lary disease at diagnosis, treated with thalidomide plusFigure 2 Photograph of patient’s soft tissue mass in the left
antecubital fossa.dexamethasone upfront, who developed eMM during
treatment although they were able to achieve fall in mono-
clonal paraprotein levels and clearance of marrow plasma-
cytosis [15]. Terpos et al. [10] described no definitive
advantage by comparing different treatment strategies for
eMM recurrence, including local radiotherapy and/or
chemotherapy, followed with or without a second ASCT
(Table 1). The median time from ASCT to relapse of EMP
was 24 months (compared to 12 months in our patient).
Although it remains to be clearly elucidated, several
mechanisms have been postulated to explain this differ-
ential response. IMiDs via their antiangiogenic and
immunomodulating properties can cause alteration in
production of interleukin-6 and tumor necrosis factor-
a, and decreased adhesion of neoplastic plasma cells.
This loss of cell-to-cell interactions within the bone
marrow microenvironment may lead to metastasis of
malignant plasma cells to extramedullary sites resulting
in eMM. This phenomenon indicates that eMM cells
have the ability to grow in the absence of bone marrow
milieu and hence circumvent antiangiogenic or immu-
nomodulatory effects of IMiDs [21]. Loss of CD56 or
Figure 4 Positron emission tomography scan showing
metabolic activity in the numerous intra-abdominal and left
inguinal soft tissue masses.
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on the primary MM cells appeared to promote eMM re-
currence with more aggressive histology and higher prolif-
eration index [16]. In addition, mutations in K-Ras [22]
and difference in chemokine receptor profiles including
functionally intact CXCR4 [23] have been linked totransitioning myeloma cells from intramedullary to extra-
medullary sites. Moreover, thalidomide requires a bone
marrow microenviroment for better antimyeloma efficacy
and hence explains its poor activity in eMM [24]. Also,
there is difference in the microvascular supply between
bone marrow and eMM. In addition the plasma cells may
dedifferentiate during thalidomide treatment changing
phenotypes that promote drug resistance [25]. Hence, the
newer drugs are unable to overcome the impact of this as-
pect of disease biology and ultimately the condition be-
comes resistant to salvage chemotherapy [10]. The
pathogenesis of eMM post-ASCT is uncertain but may in-
volve re-seeding of myeloma cells (by infusion of stem
cells contaminated with MM cells during harvesting) and
metastasis of residual myeloma due to incomplete myeloa-
blation [14].
Among the new drugs, bortezomib has been shown to
have some effect in patients with eMM, in combination
with thalidomide and dexamethasone as first-line treat-
ment [20], and alone or in combination with chemother-
apy in patients with prior IMiDs exposure [26]. Although
our patient received bortezomib and tanespimycin after
treatment with thalidomide/dexamethasone and ASCT,
his eMM relapsed suggesting development of extensive
chemoresistance as supported by previous reports [10,17].
Preconditioning with high-dose chemotherapy could allow
myeloma cells to escape from marrow and subclinical me-
tastases of an extramedullary clone with a high degree of
chemoresistance [10]. Similarly, a high incidence of resist-
ant eMM is reported in reduced-intensity conditioning allo-
geneic transplant [10,27], including patients with chronic
graft-versus-host disease (GVHD). Chronic GVHD is com-
plemented by graft versus myeloma effect at the bone mar-
row level, but at eMM sites, the myeloma cells are able to
circumvent this immune-mediated effect in the absence of
a bone marrow microenvironment [27]. In these cases of
highly resistant eMMs, there is a potential role for evolving
therapeutics, such as histone deacetylase (HDAC) inhibi-
tors, heat shock protein 90 (Hsp90) inhibitors, and the
alkylphospholipid (Akt) inhibitor [28].
In the post-genomic era, certain cytogenetics are associ-
ated with unfavorable prognosis and short survival such as
IgH translocation, for example t(4;14), deletions of chro-
mosomes 13 and 17 and abnormalities of chromosome 1
(1p deletion and 1q amplification) [29]. The expression of
p53 (17p13) was more prevalent in eMM than in MM
[30]. Many of these abnormal cytogenetics were present in
our patient including del(17p), for which effective therapy
is unavailable based on current evidence. Accumulation of
genetic and epigenetic aberrations may lead to morpho-
logical progression and probably are accompanied by bio-
logically aggressive eMM [21].
In the clinical world, due to the rarity, unusual loca-
tions and high-grade histology, eMM can pose a great
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gists. The differential diagnosis in our case included a
poorly differentiated carcinoma, metastatic carcinoma,
melanoma, various lymphomas or high-grade sarcoma.
Without knowledge of prior history, the initial workup may
not reveal the diagnosis even after employing immunohis-
tochemical stains. An accurate diagnosis requires in-
creased awareness of eMM, a good clinicopathological
interaction, and a precise application of plasma cell
markers (CD138, CD38, kappa, lambda light chain) by
immunohistochemical stains.
Conclusions
Progressive eMM despite medullary response after receiv-
ing multiple standard combination therapies including
novel therapeutics and ASCT is an uncommon presenta-
tion of relapsed disease, although its incidence has been on
the rise in recent years due to the new therapeutic para-
digm in patients with MM. Several mechanisms for intra-
to-extra medullary migration and hence the differential
treatment response have been hypothesized as reviewed
above. Patients with MM who develop eMM often show an
increased lactate dehydrogenase, resistance to conventional
chemotherapy or immunomodulatory treatment, and a very
short survival. Tumor biology of eMM is different from the
medullary disease, and MM under IMiD therapy may show
extramedullary progression independent of medullary dis-
ease regression. Although promising in treating extensive
plasmacytosis of bone marrow, bortezomib may not be ef-
fective for treating all eMM relapses, or a highly chemore-
sistant clone. In such cases, there is a potential role for
evolving therapeutics, such as HDAC inhibitors, Hsp90 in-
hibitors and Akt inhibitors.Consent
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